About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Warrant (NQ:LEXXW)

0.0012 UNCHANGED
Last Price Updated: 3:34 PM EST, Jan 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Warrant

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
Via ACCESSWIRE
News headline image
Lexaria Awards Contract For Next GLP-1 Human Pilot Study
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Commence Diabetes and Weight Loss Animal Study
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
Via ACCESSWIRE
News headline image
Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Weight-Loss Results in Animal Study, Begins Eight-Week Follow-Up Study
Via CannabisNewsWire
Topics Intellectual Property
News headline image
7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Commence HYPER-H23-1 Clinical Trial
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Closing of $3.6M Registered Direct Offering
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
News headline image
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
News headline image
Lexaria's Submits Investigational New Drug Application
Via ACCESSWIRE
News headline image
Lexaria Releases Annual Letter from the CEO
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Extensive GLP-1 Study Program
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria's Investigational New Drug Application Filing Update
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Tech Lowers Blood Glucose More Effectively than Branded GLP-1 drug Semaglutide Alone, Study Shows
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria's Technology Lowers Blood Glucose More Effectively than Rybelsus(R)-Branded GLP-1 drug Semaglutide Alone in Human Pilot Study
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Shown to Improve Oral Performance of GLP-1 Drug in Human Pilot Study
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Portfolio Expansion to 37 Granted Patents
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria Granted Two New Patents in Canada
Via ACCESSWIRE
News headline image
Lexaria Announces Pricing of $1.6 Million Registered Direct Offering
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces New Studies to Examine DehydraTECH(TM)-Powered GLP-1 Drugs
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD
Via ACCESSWIRE
News headline image
Lexaria Provides Update on Investigational New Drug Application Progress
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Results from Human Oral Nicotine Study Evaluating DehydraTECH(TM)-Nicotine
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria's DehydraTECH-Nicotine Faster than ZYN and on!
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Designing Human Clinical Study of DehydraTECH-CBD for Weight Loss, Diabetes Control
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria’s Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.